BAAM
ENTA icon

Baker Avenue Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Baker Avenue Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-33
Closed -$706 – 1623
2023
Q2 		$706 Buy
+33
New +$973 ﹤0.01% 1291

Other funds holding ENTA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baker Avenue Asset Management's ENTA Position: Q3 2023 in Review

Baker Avenue Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2023, closing a stake of 33 shares — an estimated $706 sold.

Baker Avenue Asset Management first reported a position in ENTA in Q2 2023 and held it in 1 quarter. The position peaked at $706 in Q2 2023. 132 funds tracked by Wall St. Rank hold ENTA as of Q3 2023.

  • Baker Avenue Asset Management reported no remaining Enanta Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 33 Enanta Pharmaceuticals shares in Q3 2023, an estimated $706.
  • Baker Avenue Asset Management first reported a position in Enanta Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Baker Avenue Asset Management's Enanta Pharmaceuticals position peaked at $706 in Q2 2023.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2023.

Based on Baker Avenue Asset Management's 13F filing for Q3 2023, filed 15 Nov 2023.